The Effect of β Receptor Blockade Through Propranolol on Corneal Neovascularization

Simavlı, Hüseyin; Erdurmuş, Mesut; Terzi, Elçin Hakan; Bucak, Yasin Yücel; Önder, Halil; Kükner, Ahmet Şahap

doi:10.1089/jop.2013.0238

Cited by 3 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] Simavli et al in 2014 have shown topical propranolol has no significant inhibitory effect on CNV statistically. [10] While our study shows topical propranolol can inhibit CNV statistically.…”

Section: Discussionmentioning

confidence: 58%

“…The concentrations of topical Propranolol were chosen from previous studies. [10,12] All treated and control eyes were photographed using a chargecoupled device camera attached to a slit-lamp biomicroscope at ×40 magnification. Photographs were obtained before drug administration and at 1 and 2 weeks after therapy.…”

Section: Methodsmentioning

confidence: 99%

“…Hence, beta-blockers can reduce VEGF production and subsequently regression of NV. [10,11] Propranolol has no effect on the normal level of VEGF that its mechanism remained largely unknown. [11] Recent studies have shown propranolol can reduce VEGF production in oxygen-induced retinopathy.…”

Section: Introductionmentioning

confidence: 99%

“…[11][12][13] Currently, there is no evidence of propranolol effect on CNV except only one study in 2014 that reported a non-significant effect. [10] ORIGINAL ARTICLE Therefore, the present study was aimed to investigate the anti-angiogenic effects of topical administration propranolol in experimentally-induced CNV in a rabbit model.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Untitled

Kasiri

2017

AJP

View full text Add to dashboard Cite

Objective: To evaluate the effects of topical propranolol for treatment of the corneal neovascularization (CNV) in a rabbit model of corneal injury. Methods: The CNV model was induced by 3 sutures of the cornea in 20 rabbits (20 corneas). 2 weeks after CNV, all sutures were removed then rabbits were divided randomly into two groups: Groups 1 received topical propranolol 10 mg/mL and Group 2 received only topical normal saline drops as control group, in the right eyes three times a day for 2 weeks. Photographs of (CNV) were obtained before drug administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Image J1.49c software. Results:The mean percentage of CNV area estimated as 100% before treatment. At the 1 week after treatment, the mean percentage of NV area in propranolol and saline group were 78.01 ± 4.16 and 93.33 ± 4.57, respectively. Moreover, at the 2 weeks after treatment were 65.72 ± 4.15 and 84.96 ± 5.21, respectively. After 1 and 2 weeks treatment, the NV area in propranolol group was regressed more than saline group significantly (P < 0.0001). Conclusion: Topical administration of propranolol reduces CNV in the short-term, but the efficacy of long-term treatment needs more investigations.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

Kasiri

2017

AJP

View full text Add to dashboard Cite

show abstract

“…A first study observed that propranolol eye drops 0.1 and 0.05%, administered twice a day for 7 days, was not able to reduce alkali-induced corneal neovascularization in rats. [ 21 ] On the contrary, topical timolol 0.5% twice per day significantly reduced the area of neovascularization induced by silk sutures in rabbits, [ 22 ] and similar results were obtained with 1% propranolol eye drops, 3 times a day for 2 weeks, starting immediately after suture removal. [ 23 ] A more recent study, performed in mice subjected to corneal sutures, showed that 6 subconjunctival injection of 0.5% timolol significantly reduced the corneal neovascularization, the inflammatory infiltration, and the expression of VEGF, TNFα and IL-6.…”

Section: Discussionmentioning

confidence: 69%

Propranolol eye drops in patients with corneal neovascularization

Filippi¹,

Libero

Gallarati

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops.Patient concerns:Two patients with corneal neovascularization complicating the Stevens–Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops.Diagnoses:Corneal neovascularization was detected by ophthalmoscopic evaluation.Interventions:Topical treatment with propranolol eye drops at different concentrations.Outcomes:Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed.Lessons:This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization.

show abstract